^
Association details:
| Biomarker: | BCR-ABL1 E255K |
|---|---|
| Cancer: | Acute Lymphocytic Leukemia |
| Drug: | Tasigna (nilotinib) (Bcr-abl tyrosine kinase inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Excerpt:
Regimens for relapsed or refractory Ph-positive ALL…Treatment options based on BCR-ABL1 mutation profile…Nilotinib…Contraindicated mutations...T315I, Y253H, E255K/V, or F359V/C/I or G250E
